Stenberg Shatters Fibromyalgia Control Record

Share Article

Fibromyalgia shattered the Fibromyalgia control record: 77% symptom improvement in weeks with no significant side effects.

Virgil Stenberg has added one more accomplishment to an already distinguished career: the fibromyalgia control record.

After discovering the body’s inflammation control system, its defect that causes diseases of inflammation, the defect repair (Microdose Therapytm) and the 10-point pain scale, Stenberg’s Microdose Therapytm broke both the rheumatoid arthritis and Parkinson’s disease control records.

Stenberg’s interest in medicine was inspired by his wife Helen’s severe rheumatoid arthritis. Using his Microdose Therapytm, Helen became pain-free in weeks with joint destruction arrested and no significant side effects.

Subsequently, using the best clinical trial design, Microdose Therapytm broke the rheumatoid arthritis control record by averaging 75% symptom improvement with no significant side effects. Its nearest competitor, adalimumab (Humiratm), averages 61% when used in combination with methotrexate.

When a patient having both rheumatoid arthritis and fibromyalgia was treated by Microdose Therapytm, both diseases came under control simultaneously. Follow-up testing Microdose Therapytm on other patients with fibromyalgia shattered the fibromyalgia control record: 77% symptom improvement in weeks with no significant side effects. Its nearest competitor, Savellatm, averages 42% symptom improvement.

Dr. Stenberg has received a National Institutes of Health Fellowship, National Institutes of Health Career Development Award, Sigma Xi research award, American Chemical Society research award and teaching award from university students. He was named a Chester Fritz Distinguished Professor for outstanding community service, research and teaching.

The Helen Foundation promotes Microdose Therapytm for diseases from inflammation to physicians and patients to compensate for its low cost and lack of economic driving force. More information is available at and 480-783-8376.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Visit website